Labcorp Gains FDA Nod for Companion Dx in Melanoma, Strengthening Oncology Mojo

What happened

Labcorp announced FDA approval of its PGDx elio tissue complete CDx as a companion diagnostic for BRAF-variant advanced melanoma. This adds to Labcorp’s extensive oncology portfolio, which already supported over 75% of 2024 FDA drug approvals. The approval reinforces Labcorp’s scale advantage and switching costs in precision medicine, aligning with long-term demand for targeted therapies. Strategically, it bolsters the Diagnostics segment’s high-value specialty mix, potentially mitigating pricing pressure. However, while positive, this news does not address the stock’s rich valuation (~26x trailing EPS) or the ~$100M reimbursement risk from pending PAMA/CLFS changes.

Implication

This FDA nod solidifies Labcorp’s position as a go‑to partner for companion diagnostics, supporting revenue growth and margin resilience in a specialty area with favorable demographics. It adds another well‑defended revenue stream, but the stock already trades 60% above our DCF‑based estimate, implying the market has priced in a premium for such capabilities. We see the news as incrementally positive yet insufficient to change the investment thesis, given looming reimbursement cuts and high leverage. Investors should track how this and future CDx wins translate into volume and pricing, but a material rerating would require a pullback or clearer policy relief. Accordingly, we maintain our WAIT stance, viewing risk/reward as unattractive at current levels.

Thesis delta

The FDA approval incrementally strengthens Labcorp’s moat in specialty diagnostics, but does not alter our core concerns around valuation and regulatory risk. We leave our WAIT rating unchanged, as the stock remains fully priced even with this positive development. A more attractive entry point would require a meaningful price pullback or tangible improvement in free cash flow visibility relative to reimbursement headwinds.